The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2021 | 10 year follow up of rituximab and lenalidomide in low tumor burden FL
Nathan Fowler, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses results from a follow up from an open-label Phase II trial (NCT00695786) of rituximab and lenalidomide (R2) in patients with low tumor burden follicular lymphoma (FL). After 10 years follow-up, a majority of patients treated with R2 remained in remission. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
